biostudies-literaturePuvvada SDNIH/NCI Community Oncology Research ProgramBristol-Myers SquibbNational Cancer InstituteNCI NIH HHSNational Institutes of HealthNational Clinical Trials Network686-91https://www.ebi.ac.uk/biostudies/studies/S-EPMC5125530biostudies-literatureUnknown174(5)Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.British journal of haematologyOutcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.PMC5125530CA180835UG1 CA189860CA189872UG1 CA189954UG1 CA189953UG1 CA189854UG1 CA189952CA189822UG1 CA189872P30 CA060553CA180819CA189804U10 CA180835U10 CA180838CA189808UG1 CA189957CA180888CA180821CA180846CA180801U10 CA180819CA180820CA180863CA189860CA189953CA189854UG1 CA189822CA189952U10 CA180863U10 CA180820CA189954CA189957U10 CA180801U10 CA180846UG1 CA189808U10 CA180821U10 CA180888UG1 CA189804Leblanc MLi HCouban SShea TCFriedberg JWPuvvada SDRimsza LMMarcellus DCook JRLeonard JPStiff PJKahl BWinter JNSmith SMfalseOutcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.2016-01-01T00:00:00Z2016 Sep2025-04-18T20:51:55.459Z2019-03-27T02:29:59ZS-EPMC51255302707290310.1111/bjh.14100